Coherus Biosciences (CHRS) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow

UDENYCA® Performance - UDENYCA® has generated over $720 million in revenues since its launch in 2019[6] - UDENYCA® holds over 20% share of the overall pegfilgrastim market[6] - The U S healthcare system has saved approximately $2 billion since UDENYCA® launch[6] - There is an opportunity to capture approximately 70% market share of Neulasta Onpro and Neulasta pre-filled syringe[8] Biosimilar Portfolio - The late-stage biosimilar pipeline increases the potential addressable market to approximately $29 billion[8, 9] - Humira® is expected to reach over $17 billion in annual sales before biosimilar entry in 2023[13] - Coherus submitted a 351(k) BLA for its internally developed Humira® biosimilar, CHS-1420, at the end of 2020[16] - The BLA filing for Avastin® biosimilar is projected for the second half of 2021[19] Core Capabilities and Financial Strength - Coherus reported $365 million in UDENYCA® net product revenue for the nine months ended September 30, 2020[40] - Coherus had $503 million in cash and investments[40]